The Amgen vs. Sanofi-Regeneron PCSK9 Patent Saga: UPC Decision
The PCSK9 Patent dispute saw a landmark UPC ruling that reinstated Amgen’s antibody patent, clarified core principles on inventive step, sufficiency, and claim interpretation, and strengthened legal certainty for innovators developing advanced biologic therapies across the European pharmaceutical & biopharmaceutical landscape.